Archive for October, 2013

Stem Cell Therapy Treatment for Mild Autism by Dr Alok Sharma, Mumbai, India
Improvement seen in just 5 days after Stem Cell Therapy Treatment for Mild Autism by Dr Alok Sharma, Mumbai, India. After Stem Cell Therapy As reported by th...

By: Neurogen Brain and Spine Institute

Continued here:
Stem Cell Therapy Treatment for Mild Autism by Dr Alok Sharma, Mumbai, India - Video

Stem Cell Therapy Treatment for Spinal Cord Injury c6 c7 by Dr Alok Sharma, Mumbai, India
Improvement seen after Stem Cell Therapy Treatment for Spinal Cord Injury c6-c7 by Dr Alok Sharma, Mumbai, India. After Stem Cell Therapy 1. Standing toleran...

By: Neurogen Brain and Spine Institute

Continued here:
Stem Cell Therapy Treatment for Spinal Cord Injury c6 c7 by Dr Alok Sharma, Mumbai, India - Video

WBV in Spinal cord injury
using the vibration platform to stimulate quadricep and gluteal activation in spinal cord injury.

By: Exercisabilities Pt

See original here:
WBV in Spinal cord injury - Video

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/z9p4jj/diabetic) has announced the addition of the "Diabetic Retinopathy - Pipeline Review, H2 2013" report to their offering.

'Diabetic Retinopathy - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Diabetic Retinopathy, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Diabetic Retinopathy.

Scope

- A snapshot of the global therapeutic scenario for Diabetic Retinopathy.

- A review of the Diabetic Retinopathy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.

- Coverage of products based on various stages of development ranging from discovery till registration stages.

- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.

- Coverage of the Diabetic Retinopathy pipeline on the basis of route of administration and molecule type.

- Key discontinued pipeline projects.

Go here to read the rest:
Research and Markets: Diabetic Retinopathy - Pipeline Review, H2 2013

They were mystery diseases that had stumped doctors for years - adults with strange symptoms and children with neurological problems, mental slowness or muscles too weak to let them stand. Now scientists say they were able to crack a quarter of these cases by decoding the patients' genes.

Their study is the first large-scale effort to move gene sequencing out of the lab and into ordinary medical care, and it shows that high hopes for this technology are finally paying off.

"This is a direct benefit of the Human Genome Project," the big effort to decode our DNA, said Dr. Christine M. Eng of Baylor College of Medicine in Houston. "We're now able to directly benefit patients through more accurate diagnosis."

She led the study, which was published online Wednesday by the New England Journal of Medicine. It gives results on the first 250 patients referred to Baylor for a newer type of sequencing - just the DNA segments that hold the recipes for all the proteins the body needs. That's only about 1 percent of the whole genome.

Baylor has sequenced more patients beyond those in the study - 1,700 so far - and found gene flaws in 1 out of 4, Eng said.

That rate will improve as more genes are linked to diseases, but it's already much higher than the less comprehensive gene tests done now, said Rebecca Nagy, a scientist at Ohio State University and president of the National Society of Genetic Counselors.

"For some of these conditions there could be treatments that are lifesaving," she said.

Already, three people tested at Baylor were found to have a muscle disorder that can cause respiratory problems and even death. The condition is aggravated by infections and stress, and there are drugs to treat those and prevent serious episodes, Eng said.

In other cases, having a diagnosis helped parents like Lindsey and Brandon Collier decide whether to have more children. The Colliers, who live in Georgetown, Texas, about 30 miles north of Austin, searched for years for an answer to what was plaguing their son, Cannon, now 4.

"He was a pretty floppy baby" with poor muscle tone and problems eating, Lindsey Collier said. "We weren't getting any answers and they were just all over the map on everything they were testing for."

View original post here:
Gene scans help solve mystery diseases in kids, adults

Public release date: 3-Oct-2013 [ | E-mail | Share ]

Contact: Nicole Rura rura@wi.mit.edu 617-258-6851 Whitehead Institute for Biomedical Research

CAMBRIDGE, Mass. (October 3, 2013) Whitehead Institute researchers have redefined the function of a gene whose mutation causes Rett syndrome, a neurodevelopmental autism spectrum disorder. This new research offers an improved understanding of the defects found in the neurons of Rett syndrome patients and could lead to novel therapies for the disease.

"The action of the MECP2 protein is just the opposite of how it was held for the past 15 years," says Whitehead Founding Member Rudolf Jaenisch, who is also a professor of biology at MIT. "It was thought that this protein globally repressed the expression of methylated DNA. What this work shows is when you do the analysis in a way that takes cell size into accountcell size is very different in Rett neurons compared to wild typethen suddenly we can see that the protein acts like a global activator. We've defined the function of MECP2 in a totally different way."

Rett syndrome is an X-linked genetic disease affecting one in 10,000 newborn girls. Infants with the disease appear to develop normally for their first six to 18 months, at which point their movement and language skills begin to deteriorate. Loss of speech, reduced head size, breathing and heart rhythm irregularities, and autistic-like symptoms are common by age four. Some symptoms may be treated with prescription drugs, but no cure or disease-modifying therapy exists. Previous work by the Jaenisch lab has provided some hope for the families of Rett patients. In a mouse model lacking the MECP2 gene, which is mutated in approximately 95% of girls with Rett syndrome, mice injected with the protein IGF-1 had more regular breathing and heart rhythms than did untreated mice. In addition, the brains of treated mice had greater mass and more of the vital neuronal projections that are missing in Rett syndrome mice and human patients.

In the current research, Yun Li, a postdoctoral researcher in the Jaenisch lab, analyzed the global gene expression of MECP2-deficient neurons derived from human embryonic stem cells. Unlike earlier research, Li took into account the Rett neurons' smaller size when comparing their gene expression to neurons with intact MECP2. The Rett neurons had decreased mRNA transcription, reduced protein synthesis, and severe defects in the AKT/mTOR signaling pathway, which is activated by IGF-1. Li's work is published in the October 2nd issue of Cell Stem Cell.

"We have always found it strange that MECP2 mutant mice, which share many of the severe neurological problems as really sick kids with Rett syndrome, have very few transcriptional changes detectable on a microarray. That doesn't seem to support a global repressor role for the MECP2 protein. There had to be something wrong," says Li. "Now we have a much better understanding of the function of MECP2, and the severity of the disease on a cellular level. Knowing that human Rett neurons are impaired in both global transcription and translation is important for us to design therapeutic strategies for Rett. Growth factors such as BDNF and IGF-1 are known to activate the AKT/mTOR pathway and increase protein synthesis. Down the road, we are interested in further exploring the Akt/mTOR pathway, and investigate how activation of this pathway could reverse the disease."

###

This work is supported by the Simons Center for the Social Brain, Brain and Behavior Research Foundation, International Rett Syndrome Foundation, Croucher Foundation, Swedish Research Council (VR-B0086301), National Institutes of Health (NIH grants R01-HG002668, P30-CA14051, HD 045022, R37-CA084198), Koch Institute, Curt Marble Cancer Research Fund, Simons Foundation Autism Research Initiative, and Ethel Louise Armstrong Foundation.

Rudolf Jaenisch's primary affiliation is with Whitehead Institute for Biomedical Research, where his laboratory is located and all his research is conducted. He is also a professor of biology at Massachusetts Institute of Technology.

Read the original here:
Rett syndrome gene dysfunction redefined

Ral receives President of Timor-Leste President visits Genetic Engineering and Biotechnology Center

PRESIDENT Ral Castro Ruz received on September 27 President Taur Matan Ruak of the Democratic Republic of Timor-Leste, during the latters official visit to Cuba.

After the official reception ceremony, the two leaders reviewed the excellent state of bilateral relations and expressed their will to consolidate cooperation, particularly in the context of health and education. They also discussed current international issues.

During his stay, the Timor Leste President and his delegation met with scientists at the Genetic Engineering and Biotechnology Center (CIGB), where they were presented with medicines developed by this institution, such as the recognized Heberprot-P for the treatment of diabetic foot ulcers, and the vaccine against Hepatitis B, included on the 171 registers of 14 products in 57 countries, as the CIGB researchers confirmed.

Timorese Health Minister Sergio Gama Lobo showed interest in these two Cuban products and inquired into their application.

The scientists also referred to the possibility of establishing cooperation between the institution and the Timor Leste government for the treatment of foot ulcers, as a way of raising the quality of life of persons suffering from diabetes.

At the end of his visit to the Center, President Taur Matan Ruak affirmed that there are two ways of treating people in the world: one is preventative and the other curative, and the better one is that of Cuba; preventative health care.

He subsequently stated that education and innovation are key to increased collaboration between the two nations, which he reiterated before leaving the country, saying that he is seeking to consolidate relations between Timor Leste and Cuba, above all in the health and education sectors.

See the original post here:
Raúl receives President of Timor-Leste

By changing the way certain organisms process sugar, UCLA researchers have shown how to produce more biofuel.

Ethanol boosters: The bacteria in this petri dish have been genetically modified to increase the amount of biofuel that can be made from sugar.

Researchers at UCLA have opened a path to cheaper and cleaner biofuels by using genetic engineering to fundamentally change how certain organisms process sugar.

Conventional biofuels are either too expensive to compete with fossil fuels or they release so much carbon dioxide that theyre hardly worth makingor both.

The UCLA advance, which increases the amount of biofuel that can be made from sugar by 50 percent, could make it cheaper to produce biofuels from a variety of sources, especially biomass such as wood chips and grass. The U.S. biofuels industry is in desperate need of such advanceseven though Congress has mandated that a certain amount of biofuel from biomass be blended with gasoline, high costs and other factors have limited production, leading the EPA to repeatedly waive the requirement.

The UCLA work is a promising advance in biofuels technology, says Wade Robey, chief technology officer at the ethanol producer POET. He says it shows the potential of advanced genetic engineering to drastically reduce both greenhouse gas emissions and the amount of corn or biomass used to produce a gallon of biofuel.

In conventional biofuels production, sugar derived from sources such as corn and biomass is fed to yeast, which ferments it to produce ethanol. But the fermentation process wastes a third of the carbon atoms that make up sugar; rather than being used to make ethanol, the carbon is released in the form of carbon dioxide.

The UCLA researchers cobbled together genes from a variety of organisms to create an alternate way to process sugar that doesnt emit any carbon dioxide, and uses all of the carbon in sugar to make biofuel. They created genetically modified E. coli bacteria to demonstrate the process, but they say the same genetic pathway could be incorporated into other organisms, including yeast.

Anytime you use fermentation, you lose one-third of the carbon to carbon dioxide. We can retain that carbon, reduce the carbon footprint of ethanol production, and make more money, says James Liao, professor of chemical and biomolecular engineering at UCLA.

In order to use all of the carbon in sugar, its necessary to add hydrogen to the process. The source of that hydrogen and its cost relative to the cost of sugar determine both the total carbon emissions and the cost savings. Using hydrogen from natural gas is the cheapest option. But getting hydrogen from natural gas also releases carbon dioxide, offsetting some of the carbon dioxide savings of the new process. In this case, emissions from the production of ethanol would be reduced by about 50 percent. Using hydrogen made by splitting water with solar power would eliminate all of the carbon dioxide emitted during fermentation, but the cost would likely be too high for the process to be economical.

Continue reading here:
Genetically Modified Bacteria Produce 50 Percent More Fuel

Oct. 2, 2013 A genetic condition that attacks multiple organs and usually results in fatal heart problems can be detected using a new MRI technique that was developed at the University of Alberta. The discovery of this new diagnostic tool has resulted in updated clinical guidelines for the diagnosis and treatment of Fabry disease in Canada.

Faculty of Medicine & Dentistry researchers Gavin Oudit and Richard Thompson worked with Faculty colleagues Kelvin Chow and Alicia Chan on the discovery, as well as Aneal Khan from the University of Calgary. The findings were recently published in the peer-reviewed journal, Circulation -- Cardiovascular Imaging, and involved 31 Alberta patients who have the disease.

Thompson and trainee Chow developed the MRI technique known as T1 mapping which can detect heart damage and changes at early stages -- earlier than regular MRI scans or ultrasound. When this type of MRI is used on patients with Fabry disease, the scans can detect both the disease and the severity of damage to the heart. The T1 mapping method developed by Thompson's group can be easily programmed onto MRIs around the world.

"This test can uniquely identify Fabry disease by detecting microscopic changes in the heart muscle structure that are not visible on regular images," says Thompson, who works in the Department of Biomedical Engineering. "Fabry disease can look like other diseases if you only look at the whole heart structure or function, but this T1 mapping test, that can detect the tiniest changes in the heart, could identify all the patients with Fabry disease."

Oudit added: "It is very likely that this technique will become a key part in clinical examination of patients with Fabry disease. This finding will advance the clinical care of these patients around the world. The implications will be widespread.

"Heart disease is the number one cause of death for patients with Fabry disease. The earlier the disease can be pinpointed, the sooner treatment can start. The treatment for the disease halts the condition and prevents serious damage to the heart."

Fabry disease is a genetic metabolic condition that destroys the enzyme involved in fat metabolism. This enzyme breaks down fat so without it, those with the disease accumulate deadly fat deposits in their heart, kidneys and brain. The condition affects 1 in 1,500 to 3,000 people, but was originally thought to be a rare disease. Some countries now screen newborns for the condition that costs $200,000 a year to treat through monthly infusions called enzyme replacement therapy. Symptoms of the disease include: heart failure, thickened walls of the heart, exercise intolerance, fluid buildup in the legs, blackouts, inability to lie down, strokes, tingling in the hands and feet, and changes in skin pigmentation.

It is estimated that about 1,000 Albertans are living with the disease but not everyone who has the condition has been diagnosed. Sometimes people will see scores of kidney and heart specialists for years before anyone diagnoses the condition. Men can have a blood test to identify the condition, while women -- who may also carry the disease without showing symptoms -- need to undergo genetic testing. The T1 mapping test can both pinpoint the disease and assess damage to the heart.

Oudit says the discovery of the new MRI technique "is a wonderful story of collaboration -- of patients, clinicians, scientists and industry working together to find a new diagnostic tool." Oudit is a heart failure specialist who works in the Division of Cardiology in the Department of Medicine at the Mazankowski Alberta Heart Institute.

"As an organization, we are excited to be part of these developments through the research from the University of Alberta," says Mauro Chies, acting vice-president of clinical supports for Alberta Health Services. "This is a significant advancement in the detection of disease in a non-invasive environment for our patients. We hope to be able to advance these sequences on our MRIs in the near future, and look for ways to use it to evaluate and detect other disease conditions."

More:
New MRI technique detects genetic condition that attacks the heart, brain, nerves

Public release date: 3-Oct-2013 [ | E-mail | Share ]

Contact: Mount Sinai Press Office newsmedia@mssm.edu 212-241-9200 The Mount Sinai Hospital / Mount Sinai School of Medicine

NEW YORK (October 3, 2013) -- Using powerful genetic sequencing technology, a team of investigators, led by researchers at the Icahn School of Medicine at Mount Sinai, scanned the genome of hundreds of individuals, and discovered those diagnosed with autism spectrum disorder (ASD) were more likely to have gene deletions than were people without the disorder. That means those individuals -- seven percent of the study group -- had one copy of one or more genes when they should have had two.

The scientists further report, in the American Journal of Human Genetics, that their analysis suggests the deletions may result in the miswiring and altered activity of brain neurons.

"This is the first finding that small deletions impacting one or two genes appear to be common in autism, and that these deletions contribute to risk of development of the disorder," says the study's lead investigator, Joseph D. Buxbaum, PhD, Professor of Psychiatry, Genetics and Genomic Sciences and Neuroscience at the Icahn School of Medicine at Mount Sinai.

"This conclusion needs to be expanded in other independent samples of ASD so that we can truly understand how the risk manifests," he says.

That process is now ongoing, Dr. Buxbaum adds. The Autism Sequencing Consortium, a group of over 25 institutions, was awarded a $7 million grant from the National Institutes of Health to continue analyzing the genomes of thousands of ASD individuals at Mount Sinai.

First look for missing genes in autistic population

Autism, which affects about one percent of the population, is a developmental disorder thought to be caused by a complex interplay between genetic and environmental factors. Although the disorder is highly heritable, the majority of autism cases cannot be attributed to known inherited causes, Dr. Buxbaum says.

While research has indicated that there might be as many as 1,000 genes or genomic regions that contribute to ASD, most studies have looked for either single point mutations -- a change in a single letter of DNA on a gene -- or for large areas of the genome, encompassing many genes, that is altered.

Read the original post:
Genetic analysis of individuals with autism finds gene deletions

What to grow first?
Finally picked the seeds I will be starting for my first indoor garden. I will be going with TGA #39;s Cheese Quake and a fem OG Kush to give me my sixth plant. ...

By: JS Maine

Read more from the original source:
What to grow first? - Video

Genetics - Watcher of the Skies @ Teatro Coliseo, Bs As, 21/09/13.
Genetics - Watcher of the Skies (Foxtrot, 1972). Teatro Coliseo, Bs As, Argentina. Sábado 21 de Septiembre de 2013. HD Stereo.

By: Gino Zolezzi

Read the original:
Genetics - Watcher of the Skies @ Teatro Coliseo, Bs As, 21/09/13. - Video

Genetics - Dancing with the Moonlit Knight @ Teatro Coliseo, Bs As, 21/09/13.
Genetics - Dancing with the Moonlit Knight (Selling England by the Pound, 1973). Teatro Coliseo, Bs As, Argentina. Sábado 21 de Septiembre de 2013. HD Stereo.

By: Gino Zolezzi

Read this article:
Genetics - Dancing with the Moonlit Knight @ Teatro Coliseo, Bs As, 21/09/13. - Video

Genetics part 2 nonmendelian inheritance (codominance, polygene, linked gene, sex linkage etc.)
For more information, log on to- http://shomusbiology.weebly.com/ Download the study materials here- http://shomusbiology.weebly.com/bio-materials.html Non-M...

By: Suman Bhattacharjee

Read more:
Genetics part 2 nonmendelian inheritance (codominance, polygene, linked gene, sex linkage etc.) - Video

Genetics part 3 incomplete dominance and codominance
For more information, log on to- http://shomusbiology.weebly.com/ Download the study materials here- http://shomusbiology.weebly.com/bio-materials.html Incom...

By: Suman Bhattacharjee

Read more:
Genetics part 3 incomplete dominance and codominance - Video

Genetics problems 8 duplicate dominant epistasis
For more information, log on to- http://shomusbiology.weebly.com/ Download the study materials here- http://shomusbiology.weebly.com/bio-materials.html Genetics (from Ancient Greek ????????...

By: Suman Bhattacharjee

Read the original here:
Genetics problems 8 duplicate dominant epistasis - Video

Genetics problems 11 sex linked inheritance
For more information, log on to- http://shomusbiology.weebly.com/ Download the study materials here- http://shomusbiology.weebly.com/bio-materials.html Genet...

By: Suman Bhattacharjee

See more here:
Genetics problems 11 sex linked inheritance - Video

Redline Genetics, Day 22 Flower 10 02 13
The plants I in this video are in compliance with the laws of my state. Special thanks to Redline Genetics. redlinegenetics.com.

By: Primo Kush

Link:
Redline Genetics, Day 22 Flower 10 02 13 - Video

This is a rare photo of a Bryde's whale breaching off of Bangladesh. Credit: WCS-Bangladesh

Published: Oct. 3, 2013 at 4:21 PM

NEW YORK, Oct. 3 (UPI) -- A genetic study of a species of whales sometimes targeted by Japan's scientific whaling program could aid management strategies for the animals, scientists say.

The study has helped define populations and subspecies of Bryde's whale, a medium-sized and poorly understood baleen whale, the Wildlife Conservation Society reported Thursday.

The research has confirmed the existence of two subspecies -- a larger variety that inhabits offshore waters and a smaller subspecies that frequents more coastal marine habitats.

"Very little is known about Bryde's whales in terms of where populations are distributed, the extent of their range, or even relationships among them at the population, subspecies and species levels," Columbia University researcher Francine Kershaw, lead author of the study, said. "Our genetic research will help define these groups and identify populations in need of additional protection."

Bryde's whales can grows to 50 feet in length and are found in tropical, subtropical, and warm temperate waters of the Atlantic, Pacific and Indian Oceans.

In addition to the impact of scientific whaling carried out by Japan, Bryde's whale populations are at risk from ship strikes, fisheries bycatch, hydrocarbon exploration and development in coastal waters, the researchers said.

Read more:
Genetics helps identify hunted, and poorly known, whale species

A Vaccine for AIDS: Promising Research at OHSU
Date: September 27, 2013 Speakers: Dr. Louis Picker, Associate Director of OHSU #39;s Vaccine and Gene Therapy Institute and Charles Wilhoite, Chair of the OHSU Board of Directors Thank you co-presen...

By: City Club of Portland

Read the original post:
A Vaccine for AIDS: Promising Research at OHSU - Video

BMB Gene Therapy

By: Mark Kim

See the article here:
BMB Gene Therapy - Video

Cecilia Lundberg, Professor of Neuroscience, Lund University / MultiPark
Cecilia Lundberg #39;s research group is focused on developing vectors for use in gene therapy to treat diseases in the brain. Furthermore, they also aim to expl...

By: MULTIPARK

Go here to see the original:
Cecilia Lundberg, Professor of Neuroscience, Lund University / MultiPark - Video

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/nxqb6r/rosacea) has announced the addition of the "Rosacea - Pipeline Review, H2 2013" report to their offering.

'Rosacea - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Rosacea, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Rosacea.

Scope

- A snapshot of the global therapeutic scenario for Rosacea.

- A review of the Rosacea products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.

- Coverage of products based on various stages of development ranging from discovery till registration stages.

- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.

- Coverage of the Rosacea pipeline on the basis of route of administration and molecule type.

- Key discontinued pipeline projects.

Go here to see the original:
Research and Markets: Rosacea - Pipeline Review, H2 2013

Home Mail News Sports Finance Weather Games Groups Answers Screen Flickr More omg! Shine Movies Music TV Health Shopping Travel Autos Homes Mobile Yahoo News Search News Search Web Sign In Mail Help Account Info Help Suggestions Yahoo News Home Video Photos GMA Year in Review Odd Comics Travel Opinion Trending Now Who Knew? Weather The Upbeat U.S. U.S. Video GMA Education Religion Crimes and Trials Local Contributor Network Year In Review World World Video Middle East Europe Latin America Africa Asia Canada Australia/Antarctica Business Video Exclusives Today's Markets Stocks Personal Finance Marketplace Entertainment Video Clinton Concert Celebrity TV Movies Music Fashion Books Arts Theater Dear Abby Comics Odd News Sports Video NFL MLB NBA NCAAF NCAAB Soccer Cycling NHL Tennis Golf Boxing Motor Sports MMA Olympics Tech Gadgets Wireless Apple Social Media Security Open Source Gaming Apps This Could Be Big Upgrade Your Life Politics Remake America The Issues Women and Politics Press Releases Video Science Science Video Weather News Space / Astronomy Pets Dinosaurs / Fossils Biotech Energy Green Health Video Weight Loss Cancer Sexual Health Medications/Drugs Parenting/Kids Seniors/Aging Diseases/Conditions Blogs The Sideshow Katie's Take Power Players This Could Be Big Newsmakers Trending Now The Upbeat Who Knew? Nightline Fix Beyond the Headline Local Popular Search Keyword News Search

See the article here:
Gene scans solve mystery diseases in kids, adults

DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/2zlwxm/rnai) has announced the addition of Jain PharmaBiotech's new report "RNAi - Technologies, Markets and Companies" to their offering.

RNA interference (RNAi) or gene silencing involves the use of double stranded RNA (dsRNA). Once inside the cell, this material is processed into short 21-23 nucleotide RNAs termed siRNAs that are used in a sequence-specific manner to recognize and destroy complementary RNA. The report compares RNAi with other antisense approaches using oligonucleotides, aptamers, ribozymes, peptide nucleic acid and locked nucleic acid.

Various RNAi technologies are described, along with design and methods of manufacture of siRNA reagents. These include chemical synthesis by in vitro transcription and use of plasmid or viral vectors. Other approaches to RNAi include DNA-directed RNAi (ddRNAi) that is used to produce dsRNA inside the cell, which is cleaved into siRNA by the action of Dicer, a specific type of RNAse III. MicroRNAs are derived by processing of short hairpins that can inhibit the mRNAs. Expressed interfering RNA (eiRNA) is used to express dsRNA intracellularly from DNA plasmids.

Delivery of therapeutics to the target tissues is an important consideration. siRNAs can be delivered to cells in culture by electroporation or by transfection using plasmid or viral vectors. In vivo delivery of siRNAs can be carried out by injection into tissues or blood vessels or use of synthetic and viral vectors.

Because of its ability to silence any gene once the sequence is known, RNAi has been adopted as the research tool to discriminate gene function. After the genome of an organism is sequenced, RNAi can be designed to target every gene in the genome and target for specific phenotypes. Several methods of gene expression analysis are available and there is still need for sensitive methods of detection of gene expression as a baseline and measurement after gene silencing. RNAi microarray has been devised and can be tailored to meet the needs for high throughput screens for identifying appropriate RNAi probes. RNAi is an important method for analyzing gene function and identifying new drug targets that uses double-stranded RNA to knock down or silence specific genes. With the advent of vector-mediated siRNA delivery methods it is now possible to make transgenic animals that can silence gene expression stably. These technologies point to the usefulness of RNAi for drug discovery.

The markets for RNAi are difficult to define as no RNAi-based product is approved yet but several are in clinical trials. The major use of RNAi reagents is in research but it partially overlaps that of drug discovery and therapeutic development. Various markets relevant to RNAi are analyzed from 2012 to 2022. Markets are also analyzed according to technologies and use of siRNAs, miRNAs, etc.

Profiles of 161 companies involved in developing RNAi technologies are presented along with 231 collaborations. They are a mix of companies that supply reagents and technologies (nearly half of all) and companies that use the technologies for drug discovery. Out of these, 33 are developing RNAi-based therapeutics and 35 are involved in microRNAs. The bibliography contains selected 600 publications that are cited in the report. The text is supplemented with 37 tables and 11 figures.

Key Topics Covered:

Executive Summary

1. Technologies for suppressing gene function

More:
Research and Markets: Global RNAi Market Report 2013-2022: Updated Technologies, Markets and Companies Analysis